LarryDCripeMD
Oncology • Indianapolis, INAssociate Professor, Medicine, Indiana University School of Medicine
Dr. Cripe is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
535 Barnhill Dr
# ROUTE473
Indianapolis, IN 46202Phone+1 317-278-1186Fax+1 317-944-2181
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1987 - 1990
Rush University Medical CenterResidency, Internal Medicine, 1984 - 1987
Rush Medical College of Rush University Medical CenterClass of 1984
Certifications & Licensure
IN State Medical License 1995 - 2025
NC State Medical License 1987 - 1998
MI State Medical License 1993 - 1997
IL State Medical License 1985 - 1987- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Indianapolis Monthly Castle Connolly, 2013
- Top MD Consumers Checkbook
Clinical Trials
- Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Start of enrollment: 2002 Sep 17
- Azacitidine and Erythropoietin Versus Azacitidine Alone for Patients With Low-Risk Myelodysplastic Syndromes Start of enrollment: 2006 Sep 01
- Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease Start of enrollment: 2007 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 95 citationsExtramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1...Chezi Ganzel, Judith Manola, Dan Douer, Jacob M. Rowe, Hugo F. Fernandez
Journal of Clinical Oncology. 2016-10-23 - 26 citationsREVEAL‐1, a phase 2 dose regimen optimization study of vosaroxin in older poor‐risk patients with previously untreated acute myeloid leukaemiaRobert K. Stuart, Larry D. Cripe, Michael B. Maris, Maureen A. Cooper, Richard Stone
British Journal of Haematology. 2015-03-01 - 11 citationsCombination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials.Hamid Sayar, Larry D. Cripe, Antoine N. Saliba, Mohammad Abu Zaid, Heiko Konig
Leukemia Research. 2019-02-01
Press Mentions
Chuckstrong Tailgate Gala Raises More Than $2 Million, Marking a Decade of Dedication to IU Cancer ResearchAugust 5th, 2022- Cancer Interrupted Campus ‘Dad’s Weekend’ for Devoted FatherOctober 3rd, 2021
After Cancer Treatment, Complementary Care CalmsOctober 8th, 2016- Join now to see all
Grant Support
- Single-Center Phase I Study To Determine The Optimal Biologic Dose Of Cc-401National Center For Research Resources2007–2008
- Zosuquidar Trihydrochloride During Conventional Induction And Post-RemissionNational Center For Research Resources2006
- Clinical Research OfficeNational Cancer Institute2004
- Ly335979, Daunorubicin, Cytarabine In Myelogenous LeukemNational Center For Research Resources2000–2002
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
